Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT07502508

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Led by Biomea Fusion Inc. · Updated on 2026-05-12

60

Participants Needed

16

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.

CONDITIONS

Official Title

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males or females aged 18 to 70 years
  • Diagnosed with Type 2 Diabetes
  • Taking Ozempic (semaglutide injection) with stable doses for at least 3 months
  • Treated with lifestyle management and 0 to 2 additional antihyperglycemic medications (metformin and/or SGLT2 inhibitor) with stable doses
  • Metformin dose at least 500 mg/day if used
  • Ozempic dose at least 0.5 mg/week
  • HbA1c between 7.5% and 9.5%
  • Body Mass Index (BMI) between 25 and 40 kg/m2
  • Female participants of childbearing potential must have a negative pregnancy test, be non-lactating, and willing to have pregnancy tests during the study
  • Willing and able to provide informed consent and comply with study procedures
Not Eligible

You will not qualify if you...

  • Diagnosis of type 1 diabetes mellitus or secondary forms of diabetes
  • History of diabetic ketoacidosis or hyperosmolar coma within 6 months before screening
  • History of severe hypoglycemia requiring assistance or poor recognition of hypoglycemic symptoms within 6 months before screening
  • Personal or family history of MEN1, MEN2, or medullary thyroid carcinoma
  • Use of GLP-1 receptor agonists other than Ozempic, dual GIP/GLP-1 receptor agonists, sulfonylureas, meglitinides, thiazolidinediones, alpha glucosidase inhibitors, DPP4 inhibitors, bile acid sequestrants, dopamine-2 agonists, amylin, or insulin within 3 months before screening
  • Fasting plasma glucose (FPG) equal to or above 240 mg/dL

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Central Research Associates, LLC dba Flourish Research

Birmingham, Alabama, United States, 35205

Actively Recruiting

2

Hope Clinical Research

Canoga Park, California, United States, 91303

Actively Recruiting

3

Ark Clinical Research

Long Beach, California, United States, 90815

Actively Recruiting

4

Catalina Research Institute, LLC

Montclair, California, United States, 91763

Actively Recruiting

5

Paradigm Clinical Research Centers, LLC

San Diego, California, United States, 92108

Actively Recruiting

6

Southwest General Healthcare Center

Fort Myers, Florida, United States, 33907

Actively Recruiting

7

Panax Clinical Research

Miami Lakes, Florida, United States, 33014

Actively Recruiting

8

David Kavtaradze MD, Inc

Cordele, Georgia, United States, 31015

Actively Recruiting

9

Excel Clinical Research

Las Vegas, Nevada, United States, 89109

Actively Recruiting

10

Diabetes and Endocrinology Associates of Stark County

Canton, Ohio, United States, 44718

Actively Recruiting

11

Elligo Health Research, Inc.

Austin, Texas, United States, 78704

Actively Recruiting

12

Zenos Clinical Research

Dallas, Texas, United States, 75230

Actively Recruiting

13

Synergy Group Medical

Houston, Texas, United States, 77061

Actively Recruiting

14

Epic Clinical Research

Lewisville, Texas, United States, 75057

Actively Recruiting

15

Diabetes & Glandular Disease Clinic, P.A.

San Antonio, Texas, United States, 78229

Actively Recruiting

16

Burke Internal Medicine and Research

Burke, Virginia, United States, 22015

Actively Recruiting

Loading map...

Research Team

B

Biomea Fusion Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here